APU
ENZ

Alpine Partners USVI’s Enzo Biochem, Inc. ENZ Stock Holding History

Alpine Partners USVI’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-110,810
Closed -$230K – 147
2013
Q2 		$230K Buy
+110,810
New +$245K 0.07% 140

Other funds holding ENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCT
Chemung Canal Trust Elmira, New York $541M AUM 32.42% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Alpine Partners USVI's ENZ Position: Q3 2013 in Review

Alpine Partners USVI sold out of Enzo Biochem, Inc. (ENZ) in Q3 2013, closing a stake of 110,810 shares — an estimated $230K sold.

Alpine Partners USVI first reported a position in ENZ in Q2 2013 and held it in 1 quarter. The position peaked at $230K in Q2 2013. 52 funds tracked by Wall St. Rank hold ENZ as of Q3 2013.

  • Alpine Partners USVI reported no remaining Enzo Biochem, Inc. position as of Q3 2013 after selling out during the quarter.
  • Alpine Partners USVI sold 110,810 Enzo Biochem, Inc. shares in Q3 2013, an estimated $230K.
  • Alpine Partners USVI first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 1 quarter.
  • Alpine Partners USVI's Enzo Biochem, Inc. position peaked at $230K in Q2 2013.
  • 52 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2013.

Based on Alpine Partners USVI's 13F filing for Q3 2013, filed 14 Nov 2013.